Where it trades today
trading 24% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ISRG trades at 45.2x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 33.1%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- ISRG is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ISRG.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ISRG come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ISRG. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Intuitive Surgical does
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology;…
Employees
17,021
Industry
Medical Instruments & Supplies
Headquarters
Sunnyvale, United States
What analysts expect
ISRG carries a buy consensus from 29 analysts, with an average price target of $476.34 versus $393.33 today (+21.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ISRG generated $11.03B in trailing revenue (18.5% year over year), with a 28.4% net margin, and $2.62B of free cash flow, supported by $5.22B of net cash.
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ISRG beside the healthcare names it is usually measured against.
What the chart is saying
Intuitive Surgical trades at $393.33, 34.9% below its 52-week high. With a beta of 1.47, it shows more sensitivity to what the wider market does.
Questions people ask about it
Is ISRG a good buy right now?
Intuitive Surgical trades at 45.2x earnings. This is above market average, reflecting growth expectations. Current risk level is High based on 33.1% volatility.
Does ISRG pay dividends?
Intuitive Surgical does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is ISRG?
With 30-day annualized volatility of 33.1% and beta of 1.47, ISRG is classified as High risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for ISRG?
The average analyst price target for Intuitive Surgical (ISRG) is $476.34 based on 29 analyst estimates, about 21.1% above the current price of $393.33. The published range runs from $324.00 to $685.00.
How much revenue does ISRG generate?
Intuitive Surgical reported $11.03B in trailing twelve-month revenue. Revenue growth is running at 18.5% year over year. Net margin sits at 28.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.